Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced ...
Stocktwits on MSN

NEONC receives FDA written feedback on NEO212 CMC development and capsule-to-tablet transition

FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings ...

Three Biotechs Deliver Catalysts to Watch

NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves ...
The Manila Times

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 ...

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to ...